What are monoclonal antibodies? | Dotmatics
Monoclonal antibodies (MABs) are identical antibodies produced from a single immune cell designed to specifically target antigens, primarily used as therapeutic agents to treat diseases such as cancers and autoimmune disorders by neutralizing disease-related proteins with high specificity and flexible administration methods.
One of the ways our body’s immune system protects itself from dangerous substances is by producing antibodies. Antibodies are a type of protein that attaches to another form of a protein called antigens. By finding and attaching to antigens, antibodies can impact other parts of the immune system to eliminate cells associated with the given antigen.
Antibodies can be used as a cancer treatment when you design antibodies targeting specific antigens, including those on cancer cells. These antibodies are produced using a single immune cell to create identical copies of a particular antibody. These types of antibodies are called monoclonal antibodies (MABs).
What is monoclonal antibody treatment used for?
Monoclonal antibodies can be used for various purposes, such as a diagnostic tool for identifying specific proteins. However, their primary function is as therapeutic agents for treating diseases by targeting and neutralizing specific proteins involved in the disease process.
Their success as therapeutic agents is determined by their high degree of specificity and design flexibility. These characteristics enable the use of MABs to treat diseases that are caused by different proteins without affecting other proteins in the process.
How are monoclonal antibodies used?
Monoclonal antibodies can be administered in different ways, from intravenous injection to topical application. The way MABs are used in treatment depends on the type of MAB used and the specific condition being treated. This allows MABs to be used for treating cancers and autoimmune conditions.
Autoimmune conditions include skin disorders, certain types of arthritis, and various other inflammatory autoimmune disorders. Since MABs serve as a substitute for antibodies, they mimic the immune system's attack on negative cells.
Producing suitable MABs requires researchers to determine the suitable antigen to target. The nature of different cancers has led the application of monoclonal antibody treatments to be more prevalent and successful in certain types of cancers over others. MABs offer enormous potential for treatment that must be highly specific and tailored for individual patients.
Drawbacks of monoclonal antibody therapy
While monoclonal antibodies may be a powerful treatment for several diseases and conditions, they also have drawbacks. MABs are expensive to produce, making them inaccessible to many patients. Like many other types of therapeutics, MABs may cause dangerous immune system responses, including rashes, diarrhea, nausea, dizziness, and fever.
Related
A Complete Guide to Small Molecule Drugs vs Biologics: Key Differences and Where They're Merging
The traditional distinctions between small molecule drugs and biologics are diminishing as pharmaceutical companies diversify their portfolios, invest in multidisciplinary R&D, and develop hybrid modalities like antibody drug conjugates, leading to integrated manufacturing capabilities and evolving treatment options.
How Growing Demand and Cost Pressures Are Reshaping the Biologics Discovery Landscape
The biologics discovery landscape is being reshaped by growing demand and cost pressures as biologics, including monoclonal antibodies, gene, RNA, and cell therapies, gain momentum with increasing FDA approvals, substantial market growth projected to exceed $700 billion by 2030, and strong investment flows, while innovators face the challenge of delivering novel, cost-effective treatments rapidly amid financial and development complexities.
New Dotmatics solution to streamline your antibody discovery process
Dotmatics' new Luma Antibody & Protein Engineering solution, built on the AI-native Geneious Luma platform and integrated with tools like GraphPad Prism, streamlines the complex antibody discovery and development process by unifying data, teams, and experimental phases within a single, collaborative environment to enhance biologics R&D productivity and overcome challenges of siloed data and rigid workflows.
The Future of Biologics Discovery
The article discusses the transformative potential of biologics in medicine, highlighting that biologics discovery involves designing complex, biologically-derived drugs like antibodies and gene therapies, which require sophisticated technology and controlled conditions due to their sensitivity and complexity, while also addressing challenges such as workflow complexity, high costs, and safety concerns in the development process.
Multispecific Antibodies: Engineering the Non-natural
The article discusses the challenges and innovations in designing multispecific antibodies (MsAbs)—complex, non-natural biologics aimed at treating difficult diseases beyond the scope of traditional monoclonal antibodies—highlighting the need for advanced, flexible, AI-powered in silico design tools, such as those developed by Dotmatics and BioGlyph, that use building-block-based approaches to enable researchers to engineer novel biologic formats beyond rigid, predefined structures.
Dotmatics Launches BioGlyph Luma to Accelerate the Future of Protein Design & Engineering
Dotmatics has launched BioGlyph Luma, a next-generation protein design and engineering solution integrated into its Luma Scientific Intelligence Platform, which addresses the Design phase of the protein therapeutics research cycle by enabling real-time traceability, scalable registration, and seamless integration with existing scientific tools to accelerate multimodal biologic R&D workflows with precision and data-driven automation.